Medical Condition News

RSS

Using clopidogrel, PPIs increases cardiac damage risk: Study

Patients with coronary artery disease undergoing stent implantation are often prescribed the antiplatelet drug, clopidogrel. This drug prevents blood clots, but is known to have a side-effect that can cause stomach bleeding. Consequently, many users are also prescribed a proton pump inhibitor (PPI). Now, however, a meta-analysis of almost 160,000 patients carried out at the Medical University of Vienna and Wilhelminenhospital, Vienna, has shown that simultaneous use of these drugs can increase the risk of cardiac damage.

31 Aug 2010

Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications

With both bleeding und thrombotic complications having a negative effect on PCI outcomes, increasing efforts have been made to improve PCI anticoagulation regimens. Although unfractionated heparin has been the standard anti-thrombotic agent in interventional cardiology for decades, there is still no solid evidence from large clinical trials to guide its dosing during PCI.

31 Aug 2010

Disruption of structural component in heart muscle cells occurs before decline in heart function

The disruption of a structural component in heart muscle cells, which is associated with heart failure, appears to occur even before heart function starts to decline, according to a new study by researchers at the University of Iowa Roy J. and Lucille A. Carver College of Medicine.

31 Aug 2010

USAAC, HWCF enter partnership to support healthier lifestyle choices for young people

The U.S. Army Accessions Command (USAAC) and the Healthy Weight Commitment Foundation (HWCF) today announced a partnership aimed at countering the trend toward obesity among young people that could among other downsides diminish the pool of qualified young Americans available for military duty.

31 Aug 2010

Hospital admissions in Australia due to atrial fibrillation triples

A growing epidemic of the world's most common heart rhythm disorder is resulting in an alarming number of hospital admissions in Australia, according to cardiology researchers.

31 Aug 2010

Personal listening devices can impair hearing: Study

Personal listening devices like iPods have become increasingly popular among young and not so young people in recent years. But music played through headphones too loud or too long might pose a significant risk to hearing, according to a 24-year study of adolescent girls.

31 Aug 2010

African-Americans at higher risk of developing stent thrombosis

African-American race is a distinct risk factor for developing life-threatening blood clots after receiving a drug-coated stent, according to research reported in Circulation: Journal of the American Heart Association.

31 Aug 2010

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2010.

31 Aug 2010

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

Recognizing that venous interventions may potentially play an important role in treating some patients who suffer from multiple sclerosis an incurable, disabling disease the Society of Interventional Radiology has issued a position statement indicating its support for high quality clinical research to determine the safety and effectiveness of interventional M.S. treatments.

31 Aug 2010

RXR-alpha protein helps to protect pigment cells from invasive melanoma: Research

New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling "co-conspirators" in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads.

31 Aug 2010

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.

31 Aug 2010

Cell Therapy Foundation analysis calls for funding in medical research

Some of the most promising medical research conducted to treat diseases of the brain, heart, and circulatory system is moving too slowly to help millions of patients, according to the Cell Therapy Foundation, which advocates the use of adult stem cells to dramatically impact and improve the condition of patients who suffer from a variety of conditions.

31 Aug 2010

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.

31 Aug 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.

31 Aug 2010

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

31 Aug 2010

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

Politico looks at a new fight brewing over Agent Orange and how it affects programs for Vietnam Veterans. "It's a world turned upside-down from decades ago when returning soldiers had to fight to get attention for deadly lymphomas linked to the herbicide. Now the frailties of men in their 60s — prostate cancer, diabetes, heart disease — lead the list of qualified Agent Orange disabilities, and the result has been an explosion in claims — and the government's liability.

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

$Heparin enoxaparin may provide better outcomes than unfractionated heparin$

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Results from ATOLL, a phase 3 randomised trial comparing two anticoagulants in primary PCI for ST elevation MI, show that the low molecular weight heparin enoxaparin may provide better outcomes in such cases than the traditionally used unfractionated heparin.

30 Aug 2010

Medical Condition News

Using clopidogrel, PPIs increases cardiac damage risk: Study

Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications

Disruption of structural component in heart muscle cells occurs before decline in heart function

USAAC, HWCF enter partnership to support healthier lifestyle choices for young people

Hospital admissions in Australia due to atrial fibrillation triples

Personal listening devices can impair hearing: Study

African-Americans at higher risk of developing stent thrombosis

Amsterdam Molecular first half 2010 net loss in line with last year

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

RXR-alpha protein helps to protect pigment cells from invasive melanoma: Research

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Cell Therapy Foundation analysis calls for funding in medical research

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

FDA extends Prescription Drug User Fee Act date for ezogabine

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News